Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Immuno-Biological Laboratories Co., Ltd. (4570:JPX), powered by AI.
Immuno-Biological Laboratories Co., Ltd. is currently trading at ¥945. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Immuno-Biological Laboratories Co., Ltd. on Alpha Lenz.
Immuno-Biological Laboratories Co., Ltd.'s P/E ratio is 35.3.
“Immuno-Biological Laboratories Co., Ltd. trades at a P/E of 35.3 (premium valuation) with strong ROE of 17.9%. 3Y revenue CAGR of 14.4% highlights clear growth momentum.”
Ask for details →Immuno-Biological Laboratories Co., Ltd. is a biotechnology company specializing in the research, development, and sale of diagnostic reagents and devices. The primary function of the company is to produce and supply cutting-edge immunological products used in clinical testing and life sciences research. Its offerings include various enzyme-linked immunosorbent assay (ELISA) kits, monoclonal and polyclonal antibodies, and other biochemical tools that play a crucial role in detecting and quantifying proteins, hormones, and other biomolecules. These products are pivotal for hospitals, laboratories, and research institutions in sectors such as healthcare, pharmaceuticals, and academic research. Immuno-Biological Laboratories Co., Ltd. is recognized for its contributions to advancing diagnostic capabilities and enhancing biomedical research methodologies. Its presence in the market underscores the increasing global demand for reliable and efficient diagnostic testing solutions, reflecting the expanding scope of personalized medicine and preventative healthcare measures.
“Immuno-Biological Laboratories Co., Ltd. trades at a P/E of 35.3 (premium valuation) with strong ROE of 17.9%. 3Y revenue CAGR of 14.4% highlights clear growth momentum.”
Ask for details →Immuno-Biological Laboratories Co., Ltd. (ticker: 4570) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 58 employees. Market cap is $8.8B.
The current price is 945 with a P/E ratio of 35.34x and P/B of 5.81x.
ROE is 17.92% and operating margin is 21.59%. Annual revenue is $970M.